6.30
Tenax Therapeutics Inc stock is traded at $6.30, with a volume of 4,768.
It is down -0.94% in the last 24 hours and up +5.53% over the past month.
See More
Previous Close:
$6.36
Open:
$6.48
24h Volume:
4,768
Relative Volume:
0.11
Market Cap:
$25.22M
Revenue:
-
Net Income/Loss:
$-14.56M
P/E Ratio:
-0.3746
EPS:
-16.82
Net Cash Flow:
$-12.46M
1W Performance:
+2.74%
1M Performance:
+5.53%
6M Performance:
+88.62%
1Y Performance:
+62.79%
Tenax Therapeutics Inc Stock (TENX) Company Profile
Name
Tenax Therapeutics Inc
Sector
Industry
Phone
919-855-2100
Address
101 GLEN LENNOX DRIVE, CHAPEL HILL, NC
Compare TENX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
TENX
Tenax Therapeutics Inc
|
6.30 | 25.22M | 0 | -14.56M | -12.46M | -16.82 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Tenax Therapeutics Inc Stock (TENX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Oct-24-24 | Initiated | Leerink Partners | Outperform |
Oct-14-24 | Initiated | Guggenheim | Buy |
Sep-30-24 | Initiated | William Blair | Outperform |
May-18-17 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
Dec-16-14 | Initiated | MLV & Co | Buy |
Nov-18-14 | Initiated | WallachBeth | Buy |
View All
Tenax Therapeutics Inc Stock (TENX) Latest News
Tenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - The Manila Times
Exclusive: Tenax Leadership Team to Unveil Latest Phase 3 Progress at Major Healthcare Conference - Stock Titan
What is Leerink Partnrs’ Forecast for TENX Q1 Earnings? - Defense World
Equities Analysts Offer Predictions for TENX Q1 Earnings - Defense World
Q1 Earnings Estimate for TENX Issued By William Blair - Defense World
Tenax Therapeutics (NASDAQ:TENX) Earns Sell Rating from Analysts at StockNews.com - Defense World
Research Analysts Set Expectations for TENX Q1 Earnings - Defense World
When (TENX) Moves Investors should Listen - news.stocktradersdaily.com
Tenax Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Tenax Therapeutics: Q4 Earnings Snapshot - CT Insider
Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - The Manila Times
Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides - Bluefield Daily Telegraph
Tenax Raises Massive $125M War Chest: Phase 3 Heart Failure Drug Trial Gets Major Boost - Stock Titan
Tenax Therapeutics Inc expected to post a loss of 42 cents a shareEarnings Preview - TradingView
Tenax Therapeutics (NASDAQ:TENX) Now Covered by Analysts at StockNews.com - Defense World
Tenax Therapeutics (TENX) to Release Earnings on Thursday - Defense World
Plastic Fencing Market to be Driven by Growing Residential and Commercial Construction Activities, Exclusive Research by The Insight Partners - GlobeNewswire Inc.
Tenax Therapeutics (NASDAQ:TENX) Given “Outperform” Rating at William Blair - Defense World
Promising Developments and Financial Backing Drive Buy Rating for Tenax Therapeutics - TipRanks
What is Roth Capital’s Estimate for TENX FY2024 Earnings? - Defense World
Roth Capital Predicts Weaker Earnings for Tenax Therapeutics - Defense World
(TENX) Proactive Strategies - news.stocktradersdaily.com
Tenax Therapeutics Announces $25 Million Private Placement - GlobeNewswire
Tenax Therapeutics announces $25M private placement - MSN
Tenax Therapeutics prices 378,346 shares at $6.04 in private placement - TipRanks
Tenax Therapeutics expands Phase 3 LEVEL program for TNX-103 - TipRanks
Tenax Therapeutics secures $25 million in private placement - Investing.com India
Tenax Therapeutics Announces $25 Million Private Placement -March 05, 2025 at 08:54 am EST - Marketscreener.com
Tenax Therapeutics secures $25 million in private placement By Investing.com - Investing.com UK
Tenax Therapeutics Secures $25 Million From RTW Investments For Phase 3 Clinical Trials - StockTitan
Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing - GlobeNewswire
Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing Two TNX-103 (Oral Levosimendan) Registrational Studies for the Treatment of PH-HFpEF - Yahoo Finance
Bristol Myers’ MyoKardia unit ends work with Fulcrum; ALX discloses layoffs - Endpoints News
Tenax Therapeutics to Participate in the Leerink Partners 2025 Global Healthcare Conference - The Manila Times
Can Tenax Therapeutics' Conference Appearance Signal New Cardiovascular Treatment Progress? - StockTitan
Investor Network Invites You to the Tenax Therapeutics Fiscal Year 2016 Business Review and Update Conference Call and Webcast on Tuesday, March 21, 2017 - ACCESS Newswire
Tenax Therapeutics appoints new VP of Clinical Operations - MSN
Tenax Therapeutics (NASDAQ:TENX) Shares Pass Above 200 Day Moving Average – What’s Next? - Defense World
How the (TENX) price action is used to our Advantage - Stock Traders Daily
Leerink Partnrs Weighs in on TENX FY2029 Earnings - Defense World
David Risinger Recommends Buy for Tenax Therapeutics Amid Promising Phase 3 Trials and Growth Potential - TipRanks
Tenax Therapeutics (NASDAQ:TENX) Share Price Passes Above 200-Day Moving Average – What’s Next? - Defense World
Tenax Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference - GlobeNewswire
Exclusive: Tenax CEO to Reveal Latest Cardiovascular Drug Pipeline Updates at Major Biotech Conference - StockTitan
Tenax Therapeutics (NASDAQ:TENX) Stock Price Crosses Above 200 Day Moving Average – What’s Next? - Defense World
Tenax Therapeutics Appoints Gillian Andor Vice President, Clinical Operations - The Manila Times
Tenax Therapeutics Inc Stock (TENX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):